ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK 879407 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 141.3M shares as of Jul 30, 2026 (10-Q). Share count fell from 71.8M to 10.5M between Aug 1, 2011 and Dec 15, 2011, a pattern consistent with a reverse split (roughly 1-for-7); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Pre Funded Warrants | 1.6M | $0.001 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 4, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 80,000 underlying shares, as reported Mar 31, 2018 (10-Q).
Reported exercise price: $0.001 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 141.3M = 141.3M O/S + 80,000 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Notes | $700.0M | $700.0M | $87.07 | 0% | ~8.0M sh |
If every note above converted at its tagged price: ~8.0M new shares on 141.3M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 4, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 141.3M | Jul 30, 2026 |
| + Pre Funded Warrants (if exercised) | 1.6M | Jan 7, 2026 |
| + Convertible Notes (if fully converted) | 8.0M | Jan 31, 2026 |
| Fully diluted estimate | 150.8M | +6.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $500.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 4 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ARWR workspace